Aligos Therapeutics (ALGS) Financials: Revenue & Earnings

ALGS price $5.17 +0.43 +9.07%

Ticker
ALGS
Price
$5.17
Change
+0.43 +9.07%
Market cap ?
$32.28M
P/E ?
-0.68
Forward P/E ?
12.80
Dividend yield ?
0.00%
Beta ?
2.36
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
62
Value
59
Quality
28
Growth
100

Stocklytics score rationale: value 59, quality 28, growth 100.

Financials

20182019202020212022202320242025
0004359000139070001552900039450002186000

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for significant unmet medical needs in both viral and liver diseases. Key candidates in its pipeline include ALG-010133, an s-antigen transport-inhibiting oligonucleotide polymer, which is currently undergoing Phase Ib clinical trials for chronic hepatitis B (CHB). Another asset for CHB, ALG-000184…

Fair value

ALGS fair value $9.40. Price $5.17. Price is 45% below fair value.

Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.

Calculated with a 10-year free-cash-flow discount. Starting free cash flow 207.09K. Growth 20.00%. When analyst earnings forecasts are available, free cash flow in those years is forecast earnings times the company's usual conversion of earnings into free cash flow, kept between 60% and 130%. Years with fewer than 3 analyst estimates are left out. Growth then fades in a straight line to terminal growth by year 10, starting from the last well-covered year's growth, or from the pace across those years when the final year slows sharply, kept between 0% and 20%. Without those forecasts, year-1 growth is analyst revenue growth for the next full fiscal year, or 5-year historical revenue growth when that forecast is missing, held for five years, then fading in a straight line to terminal growth by year 10. Terminal growth 3.00%. Discount rate 12.00% (beta 2.0). Beta is kept between 0.8 and 2.0, which on its own would make the discount rate 8.7% to 15.3%. The rate is then capped at 12%. A cap is used because a discount above 12% pushes higher-beta stocks further from the price. The discount rate stays at least 5 percentage points above terminal growth. Shares 6.24M. Net debt -13.05M. The earnings value is next-12-months earnings per share, or trailing earnings when that forecast is missing, times the median P/E of the company's industry. That median uses listed stocks worth at least $10 billion with a positive P/E of 100 or below, and the industry needs at least eight of them. Otherwise the sector median is used when that group also has at least eight, then the market median of those large companies. The multiple used is the lower of that median and 1.25 times the stock's own 10-year median P/E, then kept between 8 and 30. If the stock has no 10-year median, the peer median is kept between 8 and 30. Fair value is the average of the cash-flow value and the earnings value when both exist. Card and credit companies use the earnings value only, because changes in customer receivables distort free cash flow. Model uncertainty is high when fair value is more than 60% from the price, or when most of the cash-flow value sits after year 10.

Compare ALGS

Earnings

DateEPS actualEPS estimateRevenueRevenue estimate
2026-11-05—-2.44—4.85M
2026-08-06-0.14-1.0927.78M24.68M
2026-05-07-2.21-2.292.83M250.00K
2026-03-05-1.91-2.49169.00K440.00K
2025-11-06-3.04-2.09741.00K266.67K
2025-08-06-1.53-2.35965.00K433.33K
2025-05-06-2.11-2.80311.00K500.00K
2025-03-10-13.08-2.63629.00K433.33K
2024-11-06-3.07-2.151.27M433.33K
2024-08-060.75-4.001.06M—
2024-05-07-5.50-4.75986.00K—
2024-03-12-5.50-6.752.68M1.60M
2023-11-02-10.25-12.003.24M1.60M
2023-08-03-10.75-12.506.89M—
2023-05-04-13.25-12.252.72M1.42M
2023-03-09-12.75-12.253.54M1.72M
2022-11-02-11.00-14.254.11M750.00K
2022-08-04-0.47-16.253.69M4.80M
2022-05-04-0.84-16.502.57M2.18M
2022-03-10-0.89-0.83367.00K—
2021-11-04-19.50-20.751.54M1.63M
2021-08-05-19.75-20.251.54M1.54M
2021-05-10-18.50-22.50910.00K1.07M
2021-03-23-1.09-0.82——
2020-11-25-11.00-0.782.03M—
2020-10-19-0.95———
2020-03-31-0.91———
2019-12-31-0.83———
2019-09-30-0.64———
2019-06-30-0.46———
2019-03-31-0.46———
2018-06-30-0.16———
2018-03-31-0.16———

Dividends

Yield 0.00%. Payout ratio 0.00%. Frequency —.

Safety score 37/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.

Ex-dateDividendRecordPaymentFrequency
No data yet.

Insider trades

DateInsiderActionSharesPriceValue
2026-06-25Preston HeatherBuy5.86K$5.5032.23K
2026-06-25Chavez MargaritaBuy5.86K$5.5032.23K
2026-06-25Martell Bridget ABuy5.86K$5.5032.23K
2026-06-25Scopa James PaulBuy5.86K$5.5032.23K
2026-06-25Nuechterlein CaroleBuy5.86K$5.5032.23K
2026-06-25Hirth PeterBuy5.86K$5.5032.23K
2026-03-09Symons Julian A.Buy23.31K$7.03163.87K
2026-03-09Aneja NikhilBuy9.45K$7.0366.43K
2026-03-09Calhoun Lesley AnnBuy37.48K$7.03263.52K
2026-03-09BLATT LAWRENCEBuy105.84K$7.03744.06K
2026-01-29Aneja NikhilOther3.80K$16.0060.80K
2026-01-29Aneja NikhilOther2.64K$11.7430.99K
2026-01-29Aneja NikhilOther7.16K$16.87120.70K
2026-01-29Aneja NikhilOther3.60K$8.6831.25K
2025-07-16BLATT LAWRENCEBuy179.80K$8.681.56M
2025-07-16Symons Julian A.Buy16.00K$8.68138.88K
2025-07-16Calhoun Lesley AnnBuy40.19K$8.68348.81K
2025-06-25Nuechterlein CaroleBuy5.86K$7.6344.71K
2025-06-25Scopa James PaulBuy5.86K$7.6344.71K
2025-06-25Hirth PeterBuy5.86K$7.6344.71K
2025-06-25Preston HeatherBuy5.86K$7.6344.71K
2025-06-25Chavez MargaritaBuy5.86K$7.6344.71K
2025-06-25Martell Bridget ABuy5.86K$7.6344.71K
2025-02-28BLATT LAWRENCEBuy140.10K$16.872.36M
2025-02-28Symons Julian A.Buy21.69K$16.87365.96K
2025-02-28Calhoun Lesley AnnBuy47.27K$16.87797.46K
2024-10-08Achneck HardeanBuy75.00K$7.32549.00K
2024-09-23Achneck HardeanOther0——
2024-09-04Calhoun Lesley AnnBuy10.88K$11.74127.73K
2024-09-04BLATT LAWRENCEBuy33.92K$11.74398.22K
2024-09-04Symons Julian A.Buy10.88K$11.74127.73K
2024-08-07Chavez MargaritaBuy120.00K$0.5566.00K
2024-08-07Preston HeatherBuy120.00K$0.5566.00K
2024-08-07Chavez MargaritaOther0——
2024-08-07Preston HeatherOther0——
2024-06-27Hirth PeterBuy60.00K$0.3822.80K
2024-06-27Nuechterlein CaroleBuy60.00K$0.3822.80K
2024-06-27Scopa James PaulBuy60.00K$0.3822.80K
2024-06-27Martell Bridget ABuy60.00K$0.3822.80K
2024-03-01McClure Matthew W.Buy72.00K$1.1381.36K
2024-03-01Calhoun Lesley AnnBuy308.94K$1.13349.10K
2024-03-01Symons Julian A.Buy72.00K$1.1381.36K
2024-03-01BLATT LAWRENCEBuy965.43K$1.131.09M
2024-02-28Hirth PeterBuy4.41K$0.964.23K
2024-02-28Scopa James PaulBuy8.82K$0.968.47K
2024-02-28McClure Matthew W.Buy75.18K$0.9672.18K
2024-02-28McClure Matthew W.Buy65.71K$0.9663.08K
2024-02-28McClure Matthew W.Buy16.43K$0.9615.77K
2024-02-28Calhoun Lesley AnnBuy75.00K$0.9672.00K
2024-02-28Calhoun Lesley AnnBuy51.83K$0.9649.76K
2024-02-28Calhoun Lesley AnnBuy18.75K$0.9618.00K
2024-02-28BLATT LAWRENCEBuy231.00K$0.96221.76K
2024-02-28BLATT LAWRENCEBuy132.35K$0.96127.06K
2024-02-28BLATT LAWRENCEBuy57.75K$0.9655.44K
2024-02-28Symons Julian A.Buy75.00K$0.9672.00K
2024-02-28Symons Julian A.Buy58.82K$0.9656.47K
2024-02-28Symons Julian A.Buy18.75K$0.9618.00K
2024-02-28Nielsen JackBuy4.41K$0.964.23K
2024-02-28Nuechterlein CaroleBuy4.41K$0.964.23K
2024-02-28Martell Bridget ABuy8.82K$0.968.47K
2024-02-27Hirth PeterSell15.00K$26.58398.70K
2024-02-27Scopa James PaulSell30.00K$29.10873.00K
2024-02-27McClure Matthew W.Sell23.00K$3.0670.38K
2024-02-27McClure Matthew W.Sell255.63K$16.184.14M
2024-02-27Calhoun Lesley AnnSell176.24K$16.182.85M
2024-02-27Calhoun Lesley AnnSell26.25K$3.0680.33K
2024-02-27BLATT LAWRENCESell450.00K$16.187.28M
2024-02-27BLATT LAWRENCESell80.85K$3.06247.40K
2024-02-27Symons Julian A.Sell200.00K$16.183.24M
2024-02-27Symons Julian A.Sell26.25K$3.0680.33K
2024-02-27Nielsen JackSell15.00K$26.58398.70K
2024-02-27Nuechterlein CaroleSell15.00K$26.58398.70K
2024-02-27Martell Bridget ASell30.00K$16.52495.60K
2023-10-25ROCHE HOLDING LTDOther0——
2023-10-25ROCHE HOLDING LTDOther3.97M$0.763.00M
2023-10-25Nuechterlein CaroleBuy7.93M$0.766.00M
2023-10-25Nuechterlein CaroleBuy3.97M$0.763.00M
2023-10-25BLATT LAWRENCEBuy610.28K$0.76461.86K
2023-10-25BLATT LAWRENCEBuy305.14K$0.76230.93K
2023-10-25Scopa James PaulBuy183.08K$0.76138.56K
2023-10-25Scopa James PaulBuy91.54K$0.7669.28K
2023-09-08McClure Matthew W.Buy48.00K$0.8440.32K
2023-09-08Calhoun Lesley AnnBuy48.00K$0.8440.32K
2023-09-08Quan Lucinda Y.Buy48.00K$0.8440.32K
2023-09-08Symons Julian A.Buy48.00K$0.8440.32K
2023-09-08BLATT LAWRENCEBuy150.00K$0.84126.00K
2023-07-20Martell Bridget ABuy20.00K$1.0020.00K
2023-07-20Nielsen JackBuy20.00K$1.0020.00K
2023-07-20Hirth PeterBuy20.00K$1.0020.00K
2023-07-20Scopa James PaulBuy20.00K$1.0020.00K
2023-07-20Nuechterlein CaroleBuy20.00K$1.0020.00K
2023-03-15McClure Matthew W.Buy75.00K$1.34100.50K
2023-03-15Symons Julian A.Buy78.75K$1.34105.53K
2023-03-15Calhoun Lesley AnnBuy78.75K$1.34105.53K
2023-03-15Quan Lucinda Y.Buy78.75K$1.34105.53K
2023-03-15Beigelman LeonidBuy169.50K$1.34227.13K
2023-03-15BLATT LAWRENCEBuy242.50K$1.34324.95K
2022-07-07McClure Matthew W.Buy46.00K——
2022-07-07Quan Lucinda Y.Buy52.50K——
2022-07-07Quan Lucinda Y.Buy52.50K$1.4174.03K

Institutional holders

Latest filed quarter: Q2 2026.

Institutions holding: 31, holders -3 vs prior quarter. Ownership 21.98%.

HolderSharesChangeChange %Value
DEEP TRACK CAPITAL, LP444.11K00.00%2.56M
ALYESKA INVESTMENT GROUP, L.P.412.00K00.00%2.38M
SIO CAPITAL MANAGEMENT, LLC327.24K00.00%1.89M
MARSHALL WACE, LLP246.58K-20.56K-7.69%1.42M
WOODLINE PARTNERS LP177.36K00.00%1.02M
VANGUARD CAPITAL MANAGEMENT LLC175.54K-2.72K-1.53%1.01M
BAKER BROS. ADVISORS LP83.06K00.00%479.23K
HHLR ADVISORS, LTD.76.25K00.00%439.94K
D. E. SHAW & CO., INC.66.46K55.48K+505.42%383.49K
UBS GROUP AG59.99K22.93K+61.86%346.12K
GEODE CAPITAL MANAGEMENT, LLC47.17K-2.80K-5.61%272.32K
JANE STREET GROUP, LLC32.40K32.40KNew186.96K
BLACKROCK, INC.30.29K17.25K+132.30%174.78K
VANGUARD FIDUCIARY TRUST CO28.61K175+0.62%165.09K
DIMENSIONAL FUND ADVISORS LP21.04K21.04KNew121.42K
VERITION FUND MANAGEMENT LLC18.89K00.00%108.98K
TREXQUANT INVESTMENT LP12.34K12.34KNew71.20K
RENAISSANCE TECHNOLOGIES LLC10.80K-89.65K-89.25%62.32K
ROCKEFELLER CAPITAL MANAGEMENT L.P.10.00K00.00%57.70K
FEDERATION DES CAISSES DESJARDINS DU QUEBEC4.65K3.70K+389.47%26.83K
GOLDEN STATE WEALTH MANAGEMENT, LLC2.67K00.00%15.43K
ROYAL BANK OF CANADA2.12K00.00%12.00K
CITIGROUP INC1.81K1.81KNew10.43K
TOWER RESEARCH CAPITAL LLC (TRC)359294+452.31%2.07K
JPMORGAN CHASE & CO344-330-48.96%1.87K

Earnings and financials

Aligos Therapeutics, Inc. (ALGS) trades at $5.17, with a market cap of $32.28M and a trailing P/E of -0.68. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.

Financials

20182019202020212022202320242025
0004359000139070001552900039450002186000

Insights · Dividends · Forecast · Financials · Learn

Stocklytics home · Screener

Aligos Therapeutics (ALGS) Financials: Revenue & Earnings

ALGS$5.17+0.43 +9.07%

$32.28M

Market Cap

-0.68

P/E

12.80

Forward P/E

62

Score

Price History